Fig. 7: GW405833 reduces neuroblastoma growth in vivo.
From: Integrative discovery of treatments for high-risk neuroblastoma
a Mice were engrafted with \(15 \ \times 1{0}^{6}\) SK-N-BE(2) cells s.c. and randomized to receive a daily i.p. injection of GW (45 mg/kg; n = 10) or vehicle (n = 12) for 8 days, starting at the appearance of palpable tumours of \({> }0.2\,{\mathrm{cm}}^{3}\). b GW405833 significantly impaired the growth of established human tumours (hierarchical linear model). c Point comparison of day 8 tumour volume. d Tumour volume increase from day 0 to day 8. e Post-mortem tumour weight after 8 days of treatment. f Cell proliferation marker MKI67, counted using ImmunoRatio plugin for ImageJ from 10 to 15 representative fields per specimen (DMSO, GW405833, n = 5; AS601245, n = 4). g Apoptosis marker cleaved PARP, counted in using ImmunoRatio plugin for ImageJ from 10 to 15 representative fields per specimen (DMSO, GW405833, n = 5; AS601245, n = 3). h Representative images of tumour histology (HE), MKI67 and c-PARP localization, bar = 100 μm. Statistics: b Mean, 95% confidence interval, p-value computed from a mixed effects model and corrected for multiple testing using bonferroni correction. c–g Mean, standard deviation, Student’s t-test.
